Ignite Creation Date:
2025-12-24 @ 3:40 PM
Ignite Modification Date:
2026-01-01 @ 10:37 AM
Study NCT ID:
NCT02420392
Status:
COMPLETED
Last Update Posted:
2016-04-21
First Post:
2015-04-11
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Effects of Dapagliflozin on the Incretin Sensitivity of the Pancreatic Beta Cell
Sponsor:
Seoul National University Hospital
Organization:
Study Overview
Official Title:
Effects of Dapagliflozin on the Incretin Sensitivity of the Pancreatic Beta Cell
Status:
COMPLETED
Status Verified Date:
2016-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To investigate the effect of dapagliflozin on the incretin sensitivity of the pancreatic beta cell.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: